ABT vs RAMP · P/E 25, rev $44.33B vs rev $812.9M
Abbott Laboratories (ABT) versus Liveramp Holdings Inc (RAMP) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
Liveramp Holdings Inc (RAMP) is a software - infrastructure company listed on US.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
Latest reported RAMP revenue for 2026-03-31 was $812.9M. Net income was $146.0M. Revenue was up 9.0% from 2025-03-31 to 2026-03-31. RAMP currently screens at market cap $2.19B.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. RAMP currently screens at market cap $2.19B.
Not investment advice. Open the ABT and RAMP stock pages for the full models.
Not investment advice.